NO REFLOW PHENOMENON

Omid Hashemifard(1)

ARYA Atherosclerosis Journal 2009, 5(3):

Date of submission: 15 Apr 2009, Date of acceptance: 12 Jun 2009

Definition

No reflow is a phenomenon in which myocardial ischemia and reduced antegrade flow occur despite the absence of proximal stenosis, spasm, dissection, or embolic cut off of major distal branches.1 In another word no reflow phenomenon means failure of restoration of myocardial flow despite removal of epicardial coronary obstruction.2 The incidence is 2% with plain balloon angioplasty (PTCA), 7% in patients undergoing rotational atherectomy, 12% for primary percutaneous coronary intervention (PCI), and much higher at 42% for PCI of degenerated Saphenous Vein Graft (SVG).3 No reflow is a strong predictor of mortality after PCI. The mortality of patients who developed no reflow has been estimated to be 8%. Predictors of no reflow include a higher plaque burden, thrombus, lipid pools by intravascular ultrasound (IVUS), higher lesion elastic membrane cross sectional area, preinfarction angina and thrombolysis in myocardial infarction (TIMI) flow grade 0 on the initial coronary angiogram.

Mechanism

The cause is mainly embolization of atheromatous material (gruel). Particles are composed of cholesterol clefts, lipid rich macrophages, fragments of fibrous cap, necrotic lesion core and fibrin. This is aggravated by microembolization of platelet-rich thrombi that release vasoactive agents (e.g., serotonin and thromboxane A2), leading to intense arteriolar vasospasm in the distal vasculature. In the animal laboratory, experimental no reflow has been shown to be due to the plugging of capillaries by red blood cells and neutrophils, myocyte contracture and local intracellular and interstitial edema.4,5

A loss of capillary autoregulation and severe microvascular dysfunction are the ultimate physiologic consequences of these microscopic anatomic alterations. Debris of varying sizes of particulate has variable effects on microcirculatory plugging. The effect of particle size on microvascular dysfunction has been mostly investigated during rotablation. Rotational atherectomy mostly creates particle size less than 6 micron. These smaller particles pass through the capillary circulation in the same manner as red blood cells. Larger particles, which comprises about 20% of the rotational atherectomy debris or particle load, are trapped in the microcirculation and contribute to slow flow and Creatine kinase (CK) elevations from this procedure.5 Some of the more common mechanisms of no reflow is shown in Table 1.

Table 1. Proposed Mechanisms of No Reflow

<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microvascular constriction and vasospasm</td>
<td>Distal embolization of thrombus or atherosclerotic debris or both</td>
</tr>
<tr>
<td>Oxygen free-radical-mediated endothelial injury</td>
<td>Capillary plugging by red blood cells and activated Neutrophils</td>
</tr>
<tr>
<td>Neutrophil-mediated endothelial cell dysfunction or Vasoconstriction</td>
<td>Intramural hematoma</td>
</tr>
<tr>
<td>Loss of capillary integrity due to completed myocardial Infarction</td>
<td></td>
</tr>
</tbody>
</table>

Differential Diagnosis

The differential diagnosis of an apparent no reflow phenomenon is dissection or acute thrombotic formation in the proximal or distal segment (which is not well appreciated by conventional angiography) and catheter damping. It is occasionally difficult to precisely differentiate these causes and it is sometimes necessary to treat all of them (for example additional stenting in the inlet and outlet of stented lesion). A transport or infusion catheter can be inserted through the wire and advanced to the distal segment of the no reflow area. Then the wire is removed. Pressure gradient between the tip of the microcatheter and guide is measured, and contrast injection through the end hole will help to make distinction between no reflow and proximal obstructive lesion. Then injection of 3-5 cc of contrast agent with slow withdrawal of the catheter into the guide is useful to reveal any proximal disease.1 The results and management are summarized in tables 2 and 3.

1- Interventional Cardiologist, Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
E-mail: hashemi365@yahoo.com

1 AYRA Atherosclerosis Journal 2009 (Fall); Volume 5, Issue 3
Table 2. Differential diagnosis of No Reflow phenomenon

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Proximal Lesion</th>
<th>No-reflow</th>
<th>Distal lesion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pressure gradient</td>
<td>(+)</td>
<td>(-)</td>
<td>(-)</td>
</tr>
<tr>
<td>Distal flow</td>
<td>Patent</td>
<td>No flow</td>
<td>Slow flow due to distal Lesion</td>
</tr>
</tbody>
</table>

Management

Supportive measures
Treatment of the no reflow phenomenon involves basic supportive measures for the patient, including fluid resuscitation, attention to oxygenation airway management, and blood pressure maintenance with pressors or inotropes (Table 4). Maintenance of blood pressure is especially important, because distal perfusion pressure is necessary for recovery from no reflow and also for delivery of pharmacologic therapy to the distal vascular bed. When no reflow occurs in the right coronary artery or inferior distribution, atropine therapy may be necessary to treat the reflex hypotension and bradycardia that may occur. Intra aortic balloon pump therapy for blood pressure support is another mainstay of treatment in refractory cases.7,8

Pharmacologic therapy
The basis of most therapies for no reflow is intracoronary pharmacotherapy, which often rapidly restores flow and reestablishes a more stable condition. A wide array of pharmacologic agents has been used for this therapy. None of them have clear proven therapeutic value in a trial setting. Most of the practice involved with pharmacotherapy for no reflow is based on operator experience and thus anecdote.

Pharmacologic agents are administered into the affected vascular bed through a distal catheter. When drugs are given through a guiding catheter, they will preferentially flow to areas that have preserved runoff. For example, when there is slow flow in the distal circumflex artery injection into a left system guide catheter will result in the injected agent going to the contralateral vessel and never reaching the target vascular bed. Thus an infusion catheter or an over the wire balloon catheter must be delivered distal to the target lesion in the distal vasculature and injections given through this catheter.1

Intracoronary nitroglycerin has been the traditional first line agent for this therapy. However the response of the no reflow phenomenon to nitroglycerin has been poor and it is not realistic to recommend this as a first line therapy. Several other agents have shown more effect (Table 5).

Agents that have shown positive results in at least small reported series include adenosine, verapamil, and nitroprusside.11,12

Intracoronary verapamil has a success rate of two thirds in cases of no reflow especially those due to rotational ablation and it also improves all patients who had no reflow during SVG intervention. Nitroglycerin had no effect in this study.

Table 3. The characteristics of No Reflow phenomenon and its differential diagnoses

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Proximal Lesion</th>
<th>No-reflow</th>
<th>Distal lesion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pressure gradient</td>
<td>(+)</td>
<td>(-)</td>
<td>(-)</td>
</tr>
<tr>
<td>Distal flow</td>
<td>Patent</td>
<td>No flow</td>
<td>Slow flow due to distal Lesion</td>
</tr>
</tbody>
</table>

Table 4. Initial evaluation and treatment of No Reflow phenomenon

Excluded: dissection, thrombus, spasm at lesion site (IVUS, distal contrast injection, or translesion pressure gradient may be useful)
Achieve adequate ACT (250-300 s with unfractionated heparin if a llb/llla inhibitor has been given, >300 s if one has not been given, and 325-375 s with direct thrombin inhibitors)
Ensure sufficient oxygenation and airway management
Treat vagal reactions (IV atropine and fluids)
Maintain adequate perfusion pressure with IV fluids, Vasopressors, inotropes, and IABP if necessary
Administer intracoronary nitroglycerin (100-200 µg up to 4 doses) to exclude epicardial spasm
Consider administering a glycoprotein llb/llla receptor Inhibitor
Administer pharmacologic agents through an infusion catheter or the central lumen of the balloon catheter to assure drug delivery to the distal bed
Table 5. Intracoronary drug therapy for No Reflow phenomenon

<table>
<thead>
<tr>
<th>First-Line Management</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenosine (10-20 µg bolus)</td>
<td></td>
</tr>
<tr>
<td>Verapamil (100-200 µg boluses or 100 µg/min up to 1000 µg total dose with temporary pacer on standby)</td>
<td></td>
</tr>
<tr>
<td>Nitroprusside (50 -00 µg bolus, up to 1000 µg total Dose)</td>
<td></td>
</tr>
</tbody>
</table>

Evidence less Strong

Rapid, moderately forceful injection of saline or blood (to “unplug” microvasculature)
Diltiazem (0.5-2.5 mg over 1 min up to 5 mg)
Papavarine (10-20 µg)
Nicardipine (200 µg)
Nicorandil (2 µg)
Epinephrine (50-200 µg)

Never Shown to Be Effective

Intracoronary nitroglycerin
Coronary artery bypass grafting
Stent placement at site of original stenosis. If widely patent
Thrombolytics (eg, urokinase, tissue plasminogen Activator)

Adenosine has similarly been evaluated in a small number of patients with positive results. In one series of vein graft intervention, adenosine was successful in the majority of cases. Multiple doses and higher doses of adenosine have been found to be more effective than low doses.

One small experience exists which demonstrates the efficacy of nitroprusside even in cases refractory to intracoronary calcium blockers.6

Forceful injection of saline or blood has been described as a method for hydraulically dislodging platelet aggregates or microthrombi from the distal vasculature.1

Intravenous and intracoronary platelet glycoprotein IIb/IIIa inhibitors have been described as successful in some cases, but the results seem to be variable. A review of the effects of IIb/IIIa inhibitor agents in more than 4000 patients in the EPIC Evaluation of 2b/3a Platelet receptor antagonist 7E3 in Preventing Ischemic Complications (and EPILOG) Evaluation in PTCA to improve Long Term Outcome with Abciximab GP 2b/3a Blockade trials failed to show any benefit from the use these agents in SVG interventions. Placebo treated patients had a 16.3% incidence of complications versus 18.6% in those received abciximab.12,13

Various other agents have been described including several other calcium channel blockers. Intracoronary has been described as effective in this setting, as well, and has an advantage because it will not cause blood pressure decline in patients in whom that is already a problem. Skelding et al identified 29 patients in whom intracoronary epinephrine was administered for coronary no reflow. Administration of a mean dose of 139 ± 189 µg resulted in establishment of TIMI grade-3 flow in 69% of patients. Mean TIMI flow increased from 1 to 2.7 (P = 0.0001). Heart rate increased on average from 72 to 86 beats per minute, but no cases of rhythm disturbances were noted. Nicardipine has been studied in animal models and was successful in patient experiences. Nicorandil and papaverine has been used with some success intravascularly.

Intracoronary thrombolytic agents are ineffective, even when thrombotic embolization is grossly visible. Mechanical disruption of these thromboemboli is probably more effective than use of thrombolytic agents.8,14

Prevention

No reflow has been a fearful complication of PCI since the inception of balloon angioplasty. It is clear that preventive measures including embolization protection devices should be used in high risk settings for the no reflow phenomenon. SVG intervention has been proven to be safer with embolization protection, and these devices should be used in conjunction virtually all SVG interventions. Mechanical thrombectomy with extraction devices has proven efficacy in preventing no reflow in setting of primary PCI of acutemyocardial infarction AMI.14,15

References